JAMA : the journal of the American Medical Association
The most recent articles from:
JAMA
-
Randomized Controlled Trial Multicenter Study
Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial.
Muvalaplin inhibits lipoprotein(a) formation. A 14-day phase 1 study demonstrated that muvalaplin was well tolerated and reduced lipoprotein(a) levels up to 65%. The effect of longer administration of muvalaplin on lipoprotein(a) levels in individuals at high cardiovascular risk remains uncertain. ⋯ Muvalaplin reduced lipoprotein(a) measured using intact lipoprotein(a) and apolipoprotein(a)-based assays and was well tolerated. The effect of muvalaplin on cardiovascular events requires further investigation.